These results suggested that HQ, FMNT and CS could manifest remarkable inhibitory activity against colon cancer mainly via reducing the phosphorylation of ERK1/2 to inhibit the ERK1/2 pathway. The gene discussed is MAPK3; the disease is malignant colon neoplasm.